TenNor Therapeutics Suzhou Ltd. Class H
HHKEX:6872101.70
HKD
+1.00
(+0.99%)
ISIN
CNE100007KG6
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Zhen Kun Ma
- Full Time Employees
- 54
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 218 Xinghu Street Suzhou JS China 215123
- IPO Date
- May 22, 2026
- Website
- tennortherapeutics.com
- Similar Companies
- Business
- Tennor Therapeutics Suzhou Co., Ltd. is a clinical-stage biotechnology company focused on discovery, development and commercialization of innovative antibacterial therapies addressing unmet medical needs in bacterial infections and bacterial metabolism–related diseases. Through its proprietary multi-targeting conjugate molecule technology, the company advances a diversified clinical and preclinical pipeline designed to overcome limitations of conventional antibiotics and improve patient outcomes. Core products and assets include rifasutenizol (TNP-2198), a first-in-class new molecular entity for Helicobacter pylori infection; rifaquizinone (TNP-2092) injection, a potential first-in-class triple-targeting antibacterial for implant-associated infections and related indications; and TNP-2092 oral, a multi-targeting antibacterial candidate targeting gut bacterial metabolism. Tennor Therapeutics operates with a broadened portfolio across drug discovery, medicinal chemistry, preclinical development, manufacturing and clinical development support, with a geographic emphasis in China (Suzhou) and other regional operations to advance its products toward regulatory approval and commercial readiness. The company was incorporated in 2013 and has its headquarters in Suzhou, China, with a corporate presence linked to its Hong Kong‑listed parent structure, Tennor Therapeutics Suzhou (SEHK: 6872). Tennor Therapeutics engages in collaborations and partnerships to advance its infectious disease programs, pursue regulatory filings, and expand its development and potential commercialization footprint across global markets. The business includes drug production and research and development activities, leveraging its pipeline of Core Products and allied candidates across Helicobacter pylori infection, implant-associated infections, ABSSSI and related bacterial metabolism disorders. Tennor Therapeutics continuously pursues strategic alliances, pipeline expansion, and potential formulation innovations to enhance delivery and therapeutic impact in its target therapeutic areas.